KOL Experience and Next Steps With Zongertinib in HER2-Positive

Joshua K. Sabari, MD, discusses his personal experience treating patients with zongertinib as part of the Beamion LUNG‑1 trial, which supported the FDA approvals of zongertinib in patients with HER2 mutation–positive non–small cell lung cancer (NSCLC). He also highlights the ongoing confirmatory phase 3 Beamion LUNG-2trial (NCT06151574) comparing zongertinib with standard of care in frontline HER2-positive NSCLC.